{
    "nct_id": "NCT03864068",
    "official_title": "Inositol Supplementation to Treat Polycystic Ovary Syndrome: A Double Blind Dose Ranging RCT (INSUPP-PCOS)",
    "inclusion_criteria": "* Women with chronic anovulation or oligomenorrhea defined as spontaneous intermenstrual periods of greater than or equal to 45 days or a total of less than or equal to 8 menses per year.\n* Women with Hyperandrogenism defined as a total testosterone greater than 50 ng/dL or a free androgen index greater than 10.\n* Women with Polycystic Ovaries on Ultrasound defined as either 12 or more follicles measuring 2-9 mm in diameter or increased ovarian volume greater than 10 cm.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 45 Years",
    "exclusion_criteria": "* Women with Hyperprolactinemia defined as 2 prolactin levels at least one week apart greater than 30 ng/mL.\n* Women with known 21-hydroxylase deficiency or other enzyme deficiency leading to the congenital adrenal hyperplasia.\n* Women with elevated FSH levels greater than 10 mIU/mL.\n* Women with uncorrected thyroid disease as per ASRM guidelines for nonpregnant subjects (TSH less than 0.45 mIU/mL or greater than 4.5 MIU/mL).\n* Women with a suspected adrenal or ovarian tumor secreting androgens\n* Women with Cushing's syndrome\n* Women on confounding medications which affect ovarian function including metformin, hormonal contraceptives or other medications for type 2 diabetes\n* Women with medical conditions that are contraindications to OTC inositol or previous allergic reactions to the supplement or to the placebo maltodextrin or inulin.",
    "miscellaneous_criteria": ""
}